Panacela Labs, Inc.

Development of the New Generation Drugs for Medical Treatment of Cancer and Infectious Diseases

Shareholders in Portfolio Company 
RUSNANO, Cleveland Biolabs, Inc.

Industry Sector 
Medicine and Pharmacology

Production Location 
Moscow, Russia
Buffalo, USA
14 highly educated employees

Investment Started:  2011

Total Budget

2.77  bln rubles
Co-investment by RUSNANO
0.78  bln rubles

Development of the anti-cancer drugs based on the molecular modulators of cellular stress, as well as the treatments against infectious diseases. Currently, company portfolio consists of 5 drug families

Panacela Labs develops a portfolio of 5 families of drug candidates.

RCABU211—a small molecule for treatment of the cancer tumors, resistant to conventional chemotherapy. Acts through inhibition of the molecular efflux mechanism within cancer cells.

MVAME03—recombinant adenovirus-based immunotherapy for local intratumoral injection, turning the tumor into de facto in situ vaccine. Works through the novel mechanism of simultaneous secretion of theTLR5 receptor and its agonistic ligand.

AKAGU52—a small molecule developed for treatment of the castration resistant variation of the prostate cancer.

AMINI77—works against broad spectrum of tumors, with mechanism of action based on suppression of c-MYC oncogene, known as a universal target, essential for growth of over 70% of human cancers.

XELRYX3—novel antibiotic against various infectious diseases, including fungi and malaria, for both topical and systemic applications.

Areas of aplication

  • Treatment of cancer and infectious diseases

Market

  • General population

Competitive advantages

Three of the drug candidates are potentially first-in-class, by mechanism of action (MOA). No drugs with such MOA are available on the market today, which may lead the company to substantial market share and high profits, if development is successful. Two other drug candidates address unmet market needs in oncology and grave infections, such as systemic candidiasis, which are not sufficiently addressed by the existing treatments.

Differentiators of the Drug Candidates

RCABU211

  • Can be applied in conjunction with conventional chemotherapy.
  • Substantially increases efficacy of the chemotherapy.
  • Does not add toxicity for normal tissues and is not toxic on its own.
  • No MRP1 inhibitors are approved for anti-cancer use, as of today.

MVAME03

  • Stimulates internal mechanisms of anti-cancer immune response. «Trains» immunocytes on the tumor cells to enable both innate and adaptive immune responses.
  • Independent of the cancer type (as long as the original solid tumor is injectable), doesn't rely on a particular oncogene.
  • Safe: (1) no need for a systemic administration, (2) builds upon natural mechanisms of immunostimulation, (3) biologic, non-toxic by nature.
  • Effective and autonomous: combines in same nanoparticle both the activator and the receptor for the immune response.
  • Most promising application is for metastatic disease.
  • Easy to administer: injected locally.

AKAGU52

  • Unique mechanism of action, leads to complete degradation of the Androgen Receptor (AR), which is critical for existence of prostate cancer cells.
  • Active towards castration-resistant/hormone-refractory prostate cancer, known to be resistant to all existing therapies.

AMINI77

  • Inhibits cMyc oncogene, known as a universal cancer target, without which no tumor growth is possible.
  • Kills cancer cells or permanently arrests their proliferation. For normal cells, however, the impact is temporary without observed long term effect.

XELRYX3

  • Represents new generation of anti-infectives.
  • Potential for broad-spectrum antibiotic with established activity towards numerous fungal species.
  • As a result of the mechanism of action, DNA intercalation, it is higly likely to block pathogen resistance.